Home›Trial›NCT06625320

🔬NCT06625320Phase 3ACTIVE NOT RECRUITING

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Study Summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Conditions

Pancreatic Cancer PDAC PDAC - Pancreatic Ductal Adenocarcinoma

Interventions / Drugs

RMC-6236 Gemcitabine nab-paclitaxel Irinotecan Liposomal irinotecan 5-fluorouracil leucovorin Oxaliplatin

View on ClinicalTrials.gov ↗

Sponsor

Revolution Medicines

Precision Oncology

Study Details

Enrollment501 participants

Primary Completion—

Lead SponsorRevolution Medicines, Inc.

Data Retrieved2026-04-11 04:26:28.070732+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.